Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma

Pancreas

Volumn 38, Issue 5, 2009, Pages 542-550

  Sorg, Carolin ^a   Schmidt, Jan ^a   Büchler, Markus W ^a   Edler, Lutz ^b   Märten, Angela ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Adjuvant treatment; Clinical research; External validity; Pancreatic adenocarcinoma

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL STUDY; EVALUATION; EXTERNAL VALIDITY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERNAL VALIDITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; TREATMENT WITHDRAWAL;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; HUMANS; PANCREATIC NEOPLASMS; PATIENT SELECTION; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 67651122934     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819d7370     Document Type: Article

References (34)

1. de Vries TW, Tobi H, Schirm E, et al. The gap between evidence-based medicine and daily practice in the management of paediatric asthma: a pharmacy-based population study from the Netherlands. Eur J Clin Pharmacol. 2006;62(1):51-55. (Pubitemid 43106316)
2. Latza U, Stang A, Bergmann M, et al. The problem of response in epidemiological studies in Germany, part I [in German]. Gesundheitswesen. 2004;66(5):326-336. (Pubitemid 38758264)
3. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY). 2005;1(1):40-45.
4. Bortz J, Döring N. Forschungsmethoden und Evaluation für Human- und Sozialwissenschaftler. 3., überarb. Aufl., Nachdr. ed. Berlin, Germany: Springer; 2003.
5. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365(9453): 82-93.
6. Begg CB, Engström PF. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 1987;5(6):962-968.
7. Chang BH, Hendricks AM, Slawsky MT, et al. Patient recruitment to a randomized clinical trial of behavioral therapy for chronic heart failure. BMC Med Res Methodol. 2004;4:8.
8. Hampton JR. Size isn't everything. Stat Med. 2002;21(19):2807-2814.
9. Garfield FB, Garfield JM. Clinical judgment and clinical practice guidelines. Int J Technol Assess Health Care. 2000;16(4):1050-1060.
10. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465.
11. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ. 1997;157(4):408-416. (Pubitemid 27384745)
12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
13. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA. 1995;273(20):1605-1609.
14. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996;156(19):2255-2260. (Pubitemid 26361920)
15. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283(19):2552-2558. (Pubitemid 30324198)
16. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286(8): 921-929. (Pubitemid 33010338)
17. Neoptolemos J, Stocken D, Friess H, et al. The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med. 2004;350: 1200-1210.
18. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277. (Pubitemid 46143304)
19. Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol [ISRCTN62866759]. BMC Cancer. 2005;5(1):37. (Pubitemid 41471956)
20. Adler G, Seufferlein T, Bischoff SC, et al. S3-guidelines "exocrine pancreatic cancer" 2007 [in German]. Z Gastroenterol. 2007; 45(6):487-523.
21. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019-1026.
22. Begg CB. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. Bull Cancer. 1987; 74(2):197-203.
23. Bornhöft G, Maxion-Bergemann S, Wolf U, et al. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol. 2006;6:56. (Pubitemid 46177990)
24. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32(1-2): 51-63.
25. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993;29A(5):698-703. (Pubitemid 23077048)
26. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685-1695.
27. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59(12):2006-2010.
28. Kosuge T, Kiuchi T, Mukai K, et al. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36(3):159-165.
29. Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005;242(4): 540-544. (Pubitemid 41428649)
30. Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222(5):638-645.
31. Safi F, Schlosser W, Falkenreck S, et al. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45(19):253-259. (Pubitemid 28067563)
32. Montgomery RC, Hoffman JP, Riley LB, et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4(7): 551-556.
33. Tumorregister-München. Available at: http://www. tumorregistermuenchen. de/facts/base/base-C25--G.pdf. Accessed 2007.
34. Leitlinie der Dt. Ges. f. Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Dt. Krebsgesellschaft (DKG). Z Gastroenterol. 2007;34(6):487-523.